A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...
Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...
Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...
Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...
CAR T-cell therapy on the National Health Service offers adults with fast-moving B-cell leukemia years of life, fewer side ...
6hon MSN
Study links stroke-induced stress response to weakened immune system and higher infection risk
A new University of Manchester and Edinburgh study published in the journal Brain, Behavior and Immunity has found that ...
Results from two clinical trials on ianalumab for Sjögren disease show favorable safety and adverse event outcomes, ...
Genmab (GMAB) stock slips as trial data for the company's lymphoma therapy Epkinly (epcoritamab) marketed with AbbVie (ABBV) falls short of expectations. Read more here.
MedPage Today on MSN
Autoimmune Anemia Is the Latest Condition Found Responsive to CAR-T Therapy
Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...
Novartis received breakthrough therapy designation from the FDA for ianalumab, a monoclonal antibody aimed at treating Sjögren’s disease. Ianalumab works by depleting B cells and blocking BAFF-R ...
North Chicago, Illinois Monday, January 19, 2026, 15:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback